{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:44:37Z","timestamp":1792100677771,"version":"4.4.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"DOI":"10.1007\/s43441-026-01055-2","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:52:49Z","timestamp":1792097569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aggregate Safety Assessment Planning in Clinical Trial Drug Development: Survey of Clinical Safety Professionals and Safety Data Scientists Advancing Premarket Safety Analytics at 21 Companies"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5626-904X","authenticated-orcid":false,"given":"Greg","family":"Ball","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"1055_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s43441-021-00268-x","volume":"55","author":"G Ball","year":"2021","unstructured":"Ball G, Hendrickson BA, Freedman AL, Gordon R, Crowe B, Veenhuizen MF, Buchanan J. Interdisciplinary Safety Evaluation for Learning and Decision-Making. Therapeutic Innov Regul Sci. 2021;55:705\u201316.","journal-title":"Therapeutic Innov Regul Sci"},{"key":"1055_CR2","unstructured":"U.S. Food and Drug Administration. Guidance for industry. Sponsor Responsibilities - Safety Reporting Requirements and Safety Assessment for IND and Bioavailability \/ Bioequivalence Studies; 2025."},{"key":"1055_CR3","unstructured":"Sandburg B. US FDA Is No Longer \u2018Getting Crap\u2019 from Sponsors in IND Safety Reports, Temple Says. Pink Sheet; 2021."},{"key":"1055_CR4","unstructured":"US Food and Drug Administration. Final Rule: Investigational New Drug Safety Reporting Requirements for Human Drug and Biological Products. and Safety Reporting Requirements for Bioavailability and Bioequivalence Studies in Humans; 2010."},{"key":"1055_CR5","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.cct.2011.05.010","volume":"32","author":"G Ball","year":"2011","unstructured":"Ball G, Piller LB, Silverman MH. Continuous safety monitoring for randomized controlled clinical trials with blinded treatment information. Contemp Clin Trials. 2011;32:S2\u201310.","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"1055_CR6","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1177\/2168479016656702","volume":"50","author":"PM Schnell","year":"2016","unstructured":"Schnell PM, Ball G. A Bayesian exposure-time method for clinical trial safety monitoring with blinded data. Therapeutic Innov Regul Sci. 2016;50(6):833\u201345.","journal-title":"Therapeutic Innov Regul Sci"},{"key":"1055_CR7","first-page":"1557","volume":"54","author":"E Goren","year":"2020","unstructured":"Goren E, Lin LA, Blaustein RO, Ball G. Bayesian meta-analysis of safety outcomes using blinded clinical trial data. Clin Trails. 2020;54:1557\u201365.","journal-title":"Clin Trails"},{"issue":"2","key":"1055_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/pst.2175","volume":"21","author":"B Waterhouse","year":"2021","unstructured":"Waterhouse B, Hartford A, Mukhopadhyay S, Ferguson R, Hendrickson BA. Using BDRIBS to Support the Decision to Refer an Event to a Safety Assessment Committee for Unblinded Evaluation. Pharm Stat. 2021;21(2):372\u201385.","journal-title":"Pharm Stat"},{"issue":"2","key":"1055_CR9","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/pst.2278","volume":"22","author":"K Brock","year":"2022","unstructured":"Brock K, Chen C, Ho S, Fuller G, Woolfolk J, McShea C, Penard N. A Bayesian method for safety signal detection in ongoing blinded randomised controlled trials. Pharm Stat. 2022;22(2):378\u201395.","journal-title":"Pharm Stat"},{"key":"1055_CR10","unstructured":"U.S. Food and Drug Administration. (2024). Guidance for industry: Use of Data Monitoring Committees in Clinical Trials."},{"issue":"5","key":"1055_CR11","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1177\/1740774509344101","volume":"6","author":"BJ Crowe","year":"2009","unstructured":"Crowe BJ, Xia HA, Berlin JA, et al. Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clin Trials. 2009;6(5):430\u201340.","journal-title":"Clin Trials"},{"key":"1055_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s43441-021-00271-2","volume":"55","author":"BA Hendrickson","year":"2021","unstructured":"Hendrickson BA, McShea C, Ball G, Bennett D, Bhattacharyya A, Fries M, Kuebler J, Kurek R, Wang WW, Tremmel L. Aggregate Safety Assessment Planning for the Drug Development Life Cycle. Therapeutic Innov Regul Sci. 2021;55:717\u201332.","journal-title":"Therapeutic Innov Regul Sci"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01055-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01055-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-01055-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:52:50Z","timestamp":1792097570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-01055-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":12,"alternative-id":["1055"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-01055-2","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"26 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GB and SM are independent consultants and could benefit from companies implementing the ASAP process. Otherwise, none of the authors have a financial or personal relationship with a third party whose interests could be positively or negatively influenced by the article\u2019s content.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}